- Source type
- Clinical resource
- Access type
- Publisher
- Publisher
- WashU Medicine
- Added
- 2026-07-08
Trust profile
VV Source Trust Matrix v1.0
VV Source Trust Matrix v1.0 asks whether this source is trustworthy for the claim lane being used, not whether every possible claim from it is equally strong.
82
Professional clinical guidance
- Publisher type
- Professional guidance
- Bias profile
- Moderate
This source is strongest for safety and consumer context and weaker for mechanism and trial discovery.
VV Source Fit Score 1.0
Fit by use case
Fit scores are role-specific. A source can be excellent for one claim lane and weak for another.
- Regulatory status
- 63/100
- Context Source
- Clinical outcomes
- 78/100
- Strong Support
- Mechanism
- 63/100
- Context Source
- Safety
- 86/100
- Strong Support
- Consumer context
- 82/100
- Strong Support
- Trial discovery
- 63/100
- Context Source
Best used for
- Clinical context
- Practice guidance
Weak for
- Replacing primary evidence
Used in Viral Vitalism
Aging Faster May Be Part of the Early-Onset Cancer Puzzle
Roles: Supporting evidence
Related studies
No structured study record is currently attached to this source.
Related sources
ClinicalTrials.gov: ReMIND trial
Canonicalized from June 30, 2026 rapid-brief batch.
- Trust score
- 84
- Publisher
- ClinicalTrials.gov
- Access
- Official
- Usage
- 1 connection
Nature Medicine: biological aging and generational shifts in early-onset cancer
Canonical source record for the republished rapid brief accelerated-biological-aging-early-onset-cancer-risk.
- Trust score
- 91
- Publisher
- Nature Medicine
- Access
- Publisher
- Usage
- 1 connection
CIRM: clinical and preclinical development awards
Canonicalized from June 30, 2026 rapid-brief batch.
- Trust score
- 91
- Publisher
- CIRM
- Access
- Official
- Usage
- 1 connection
ClinicalTrials.gov: trial registry search for FourLight-3 context
Canonical source record for the republished rapid brief jamie-lynne-tarailo-breast-cancer-trial-close-to-home.
- Trust score
- 91
- Publisher
- ClinicalTrials.gov
- Access
- Official
- Usage
- 2 connections
FDA: approves sacituzumab govitecan-hziy for first-line TNBC indications
Canonical source record for the republished rapid brief fda-trodelvy-first-line-triple-negative-breast-cancer.
- Trust score
- 94
- Publisher
- FDA
- Access
- Official
- Usage
- 1 connection
FDA: bulk drug substances for compounding that may present significant safety risks
Canonical source record for the republished rapid brief fda-peptide-review-bpc-157-tb-500-mots-c-semax-epitalon.
- Trust score
- 94
- Publisher
- FDA
- Access
- Official
- Usage
- 1 connection